The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | The impact of liso-cel approval on the CLL treatment landscape and barriers to its use
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the recent approval of lisocabtagene maraleucel (liso-cel) in the US for double-exposed, third-line patients with chronic lymphocytic leukemia (CLL) who have been heavily pre-treated. He explains the logistical challenges of administering the treatment and mentions the ongoing TRANSCEND-CLL-004 trial (NCT03331198). This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miragen Therapeutics Inc, Novartis, Oncternal Therapeutics, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, Xencor; Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair, CLL).
